Clinical TrialMay 28, 2026, 04:00 PM
Regeneron's Maftivimab Prioritized by WHO for Bundibugyo Ebola Trials
AI Summary
Regeneron Pharmaceuticals announced that maftivimab, a component of its FDA-approved Ebola treatment Inmazeb, has been recommended by the World Health Organization's (WHO) Therapeutics Advisory Group for prioritized evaluation in clinical trials for Bundibugyo ebolavirus. This recommendation follows WHO's declaration of a public health emergency due to the current Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda. Regeneron is coordinating with the U.S. Department of Health and Human Services and WHO to advance clinical evaluation and is preparing existing maftivimab supply for potential trials.
Key Highlights
- WHO recommended maftivimab for prioritized evaluation in clinical trials for Bundibugyo ebolavirus.
- Maftivimab is the most potent neutralizing antibody in Inmazeb, already approved for Zaire ebolavirus.
- Maftivimab has demonstrated broad in vitro activity against multiple Ebola species, including Bundibugyo.
- Regeneron is coordinating with the U.S. Department of Health and Human Services and WHO for clinical evaluation.
- Regeneron donated 500 doses of Inmazeb to WHO in September 2025 for low- and lower-middle income countries.
- Inmazeb was prequalified by WHO in November 2023, certifying its quality, safety, and efficacy.
- The safety and efficacy of Inmazeb were established through the 681-patient PALM Trial.
Price Impact
More from REGN